Prospective Lifespan Cohort of Myocardial Infarction

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-74
SponsorFujian Provincial Hospital

About this trial

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.

The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.

The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

6,000 Participants
are grouped into 2 trial groups
Group A: High-risk Population
Group B: Confirmed Acute Myocardial Infarction Population

Trial outcomes

Primary outcomes

1

Rate of all-cause mortality

Time frame
From enrollment to the end of study follow-up, up to 5 years

Secondary outcomes

1

Rate of cardiovascular death

Time frame
From enrollment to the end of study follow-up, up to 5 years
2

Rate of recurrent myocardial infarction

Time frame
From enrollment to the end of study follow-up, up to 5 years
3

Rate of readmission due to heart failure

Time frame
From enrollment to the end of study follow-up, up to 5 years
4

Rate of target vessel or non-target vessel revascularization

Time frame
From enrollment to the end of study follow-up, up to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: